Spoken Alpha
Pulmonx Corp
Pulmonx provides minimally invasive endobronchial valve systems to treat severe emphysema patients who remain symptomatic despite medical management and are ineligible for or unwilling to undergo surgery.
Pulmonx Corp is a Healthcare company operating in Medical Devices with a $84.2M market cap.
LUNG beat consensus EPS by 0.1% in Q2 FY2026, reported Jul 28, 2026.
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LUNG.
$ curl https://api.spokenalpha.com/v1/companies/LUNGFAQ
Spoken Alpha indexes LUNG's earnings call transcripts at https://spokenalpha.com/companies/LUNG. Each call links to attributed speakers and parsed analyst Q&A. Pulmonx Corp's own investor relations page is at https://investors.pulmonx.com/.
Pulmonx Corp (LUNG) held its most recent earnings call on 2026-04-30, covering fiscal Q1 2026.
Pulmonx Corp (LUNG) operates in the Healthcare sector (Medical Devices industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-28 | $-0.24 | $-0.28 | +14.3% | $22.8M | — | — | EODHD |
| Q1 FY2026 | 2026-04-28 | $-0.33 | $-0.33 | 0.0% | $20.6M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $-0.25 | $-0.39 | +36.7% | $22.6M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.34 | $-0.42 | +19.1% | $21.5M | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $-0.38 | $-0.40 | +5.0% | $23.9M | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $-0.36 | $-0.40 | +10.0% | $22.5M | — | — | EODHD |
| Q4 FY2024 | 2025-02-18 | $-0.33 | $-0.45 | +26.7% | $23.8M | — | — | EODHD |
| Q3 FY2024 | 2024-10-29 | $-0.36 | $-0.45 | +20.0% | $20.4M | — | — | EODHD |
| Q2 FY2024 | 2024-07-30 | $-0.35 | $-0.43 | +18.6% | $20.8M | — | — | EODHD |
| Q1 FY2024 | 2024-04-30 | $-0.36 | $-0.46 | +21.7% | $18.9M | — | — | EODHD |
| Q4 FY2023 | 2024-02-20 | $-0.36 | $-0.41 | +12.2% | $19.3M | — | — | EODHD |
| Q3 FY2023 | 2023-10-29 | $-0.39 | $-0.43 | +9.3% | $17.7M | — | — | EODHD |
| Q2 FY2023 | 2023-08-01 | $-0.43 | $-0.44 | +2.3% | $17.2M | — | — | EODHD |
| Q1 FY2023 | 2023-05-01 | $-0.42 | $-0.45 | +6.7% | $14.5M | — | — | EODHD |
| Q4 FY2022 | 2023-02-21 | $-0.38 | $-0.42 | +9.5% | $15.4M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.38 | $-0.40 | +5.0% | $13.5M | — | — | EODHD |
| Q2 FY2022 | 2022-08-01 | $-0.40 | $-0.41 | +2.4% | $13.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-02 | $-0.43 | $-0.36 | -19.4% | $10.8M | — | — | EODHD |
| Q4 FY2021 | 2022-02-22 | $-0.35 | $-0.36 | +2.8% | $13.7M | — | — | EODHD |
| Q3 FY2021 | 2021-11-01 | $-0.28 | $-0.38 | +26.3% | $13.3M | — | — | EODHD |
Source: EODHD. LUNG reported actuals as published; sparse fields render as —.